WallStSmart

Carlsmed, Inc. Common Stock (CARL)vsTempus AI, Inc. Class A Common Stock (TEM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Tempus AI, Inc. Class A Common Stock generates 2742% more annual revenue ($1.27B vs $44.75M). TEM leads profitability with a -19.3% profit margin vs -57.5%. TEM earns a higher WallStSmart Score of 31/100 (F).

CARL

Avoid

31

out of 100

Grade: F

Growth: 8.0Profit: 3.0Value: 5.0Quality: 5.0

TEM

Avoid

31

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 5.5
Piotroski: 6/9Altman Z: -2.16

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CARL2 strengths · Avg: 9.0/10
Revenue GrowthGrowth
98.4%10/10

Revenue surging 98.4% year-over-year

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

TEM1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
83.0%10/10

Revenue surging 83.0% year-over-year

Areas to Watch

CARL4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$335.19M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Free Cash FlowQuality
$-5.81M2/10

Negative free cash flow — burning cash

TEM4 concerns · Avg: 3.0/10
Price/BookValuation
16.9x4/10

Trading at 16.9x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
-89.5%2/10

ROE of -89.5% — below average capital efficiency

Free Cash FlowQuality
$-51.78M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : CARL

The strongest argument for CARL centers on Revenue Growth, Price/Book. Revenue growth of 98.4% demonstrates continued momentum.

Bull Case : TEM

The strongest argument for TEM centers on Revenue Growth. Revenue growth of 83.0% demonstrates continued momentum.

Bear Case : CARL

The primary concerns for CARL are EPS Growth, Market Cap, Return on Equity.

Bear Case : TEM

The primary concerns for TEM are Price/Book, EPS Growth, Return on Equity. Debt-to-equity of 2.63 is elevated, increasing financial risk.

Key Dynamics to Monitor

CARL is growing revenue faster at 98.4% — sustainability is the question.

CARL generates stronger free cash flow (-6M), providing more financial flexibility.

Monitor HEALTH INFORMATION SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

CARL scores higher overall (31/100 vs 31/100) and 98.4% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Carlsmed, Inc. Common Stock

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Carlsmed, Inc. develops and operates a surgical platform for the treatment of complex adult spinal deformities that enables surgeons to harness clinical intelligence, advanced image recognition, and 3D printing technologies. The company is headquartered in Carlsbad, California.

Tempus AI, Inc. Class A Common Stock

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Tempus AI, Inc is a healthcare technology company. The company is headquartered in Chicago, Illinois.

Visit Website →

Want to dig deeper into these stocks?